CurrentHealth NetPolicy CP.PHAR.232

OnabotulinumtoxinA (Botox) clinical coverage criteria

Defines medical necessity criteria, age/dose limits, prescriber requirements, step-therapy/therapeutic alternative expectations, prior authorization documentation, continuation criteria, excluded indications, and approval durations for Botox across multiple FDA-approved and selected off-label indications for Commercial, HIM/ICHRA, and Medicaid lines of business.

Policy Summary

PayerHealth Net

PolicyOnabotulinumtoxinA (Botox) clinical coverage criteria

Policy CodePolicy CP.PHAR.232

Change TypeNo material change

Effective DateJul 1, 2016

Next Review Date

Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) supporting that member has met all approval criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes — policy has no listed updates in this brief.

13Initial covered indications listed (A-M)

4Continued approval categories (A-D)

4Primary exclusions called out

Coverage Summary

Policy CP.PHAR.232 (Effective 07.01.16; Last review 05.26.2026) provides medical necessity criteria for onabotulinumtoxinA (Botox). The policy stance is covered with criteria, defining authorized FDA-approved indications and selected off‑label uses when prescriber, age, step-therapy, dosing, and documentation requirements are met.

The policy covers multiple FDA‑approved indications (see sections I.A–I.G) with indication‑specific initial and continuation criteria, age and dose limits, prescriber specialty requirements, prior‑therapy or step‑therapy expectations, and required treatment plan documentation. Selected off‑label GI and neurologic indications are included with required supporting evidence and specialist prescribing per the policy and referenced off‑label policies.

Quick thresholds & stats

Chronic migraine frequency threshold>= 15 headache days per month for at least 3 months with headaches lasting >= 4 hours/day

Pediatric 3‑month total dose limit<= lower of 10 Units/kg body weight or 340 Units per 3‑month interval

Adult 3‑month total dose limit<= 400 Units per 3‑month interval

Number of initial covered indications listed13 (A–M)

Continued approval categories4 (A–D)

Primary exclusions called out4 (cosmetic upper‑face, episodic migraine, non‑FDA uses not addressed, dose limits)

Coding and Policy References

Policy references / related clinical policiesmixed

CP.CPA.190	No coverage criteria policy (commercial) referenced for label changes or formulary status
HIM.PA.33	No coverage criteria policy (HIM) referenced
CP.PMN.255	No coverage criteria policy (Medicaid) referenced
HIM.PA.103	Non-formulary policy (HIM) referenced
CP.PMN.16	Non-formulary policy (Medicaid) referenced
CP.CPA.09	Off-label use policy (commercial) referenced
HIM.PA.154	Off-label use policy (HIM) referenced
CP.PMN.53	Off-label use policy (Medicaid) referenced

Provider Actions / Prior Authorization Requirements

Documentation Required

Support clinical documentation

Submit office chart notes, lab results, and any other clinical information (e.g., consult notes, imaging, procedure reports) that document the diagnosis, prior medication trials or failures, specialist consultation (when required), and the treatment plan including number of Units per indication and per treatment session.

Prior Authorization

Prescriber specialty requirement

Requests must be prescribed by or in consultation with the specialists listed for each indication (examples include neurologist, urologist, gastroenterologist, dermatologist, ophthalmologist, pain specialist, ENT, orthopedist, physiatrist). When the request follows a consultant-managed course of care, include consultant documentation to confirm indication, assessment, and agreement with the proposed Botox therapy.

Step Therapy

Medication trial requirements

Document prior medication trials and durations as required by indication (e.g., OAB: adult failure of an anticholinergic agent or an oral beta-3 agonist each for at least 30 days; pediatric OAB/NDO: two anticholinergics each ≥ 30 days; chronic migraine: failure of at least 2 oral preventive therapies from different classes each for 8 weeks; primary axillary hyperhidrosis: 6-month trial of topical aluminum chloride; chronic anal fissure: failure of nitroglycerin and trial of nifedipine or diltiazem per guidance; sialorrhea and other GI indications: required trials such as stool softeners/laxatives). Note: Illinois HIM requests are exempt from the step therapy requirements per IL HB 5395 effective 2026-01-01; include documentation of state/product status when invoking this exception.

Billing Rule

Dose and interval limits

Include in the treatment plan the number of Botox Units per indication and per treatment session. Follow the policy frequency and dose caps: most indications—one treatment session every 12 weeks; esophageal achalasia—one treatment session every 24 weeks. Apply the indication-specific per-session dose limits (examples: OAB ≤ 100 Units; urinary incontinence with neurologic condition ≤ 200 Units (weight ≥ 34 kg) or ≤ 6 Units/kg (weight < 34 kg); chronic migraine ≤ 155 Units initial (continued criteria allow up to 195 Units); upper/lower limb spasticity and other indication-specific caps as specified in the policy).

Denial Risk

Concurrent botulinum products and recent botulinum therapy

Claims may be denied if Botox is prescribed concurrently with other botulinum toxin products or if any botulinum toxin therapy for cosmetic or medical conditions was administered within the prior 12 weeks. Verify prior botulinum toxin treatments and document timing to avoid denials.

Background, Evidence, and Definitions

Background: OnabotulinumtoxinA (Botox) is described as an acetylcholine release inhibitor and neuromuscular blocking agent used to reduce unwanted muscle activity and secretions.

FDA‑approved indications listed in the policy include treatment of overactive bladder (OAB) including neurogenic detrusor overactivity), urinary incontinence, chronic migraine prophylaxis, spasticity (age ≥ 2 years), cervical dystonia, primary axillary hyperhidrosis (adults), blepharospasm, strabismus, and other GI/motor conditions such as esophageal achalasia, Hirschsprung disease/Internal Anal Sphincter (IAS) achalasia, chronic anal fissure, and sialorrhea where appropriate (see sections I.A–I.L).

The policy also includes selected off‑label indications (e.g., focal dystonias, essential tremor, esophageal achalasia, Hirschsprung disease/IAS achalasia, chronic anal fissure, chronic sialorrhea) which are covered when the policy's specialist prescriber, step‑therapy, dosing, and documentation requirements are met and when prescribers submit supporting evidence per the off‑label use guidance.

Evidence: The policy cites multiple specialty guideline sources supporting botulinum toxin use by indication, including the American Academy of Neurology (AAN), American Headache Society (AHS), American Academy of Otolaryngology‑Head and Neck Surgery (AAO‑HNS), American College of Gastroenterology (ACG), and the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM), among others, to support indication‑specific recommendations and dosing.

Guideline references are provided in Appendix E and the reference list to align the coverage criteria and dosing limits with authoritative specialty guidance.

Term	Definition
OAB	Overactive bladder
NDO	Neurogenic detrusor overactivity
CD	Cervical dystonia
HD	Hirschsprung disease
IAS	Internal anal sphincter
OMD	Oromandibular dystonia
UE	Upper extremity
SCM	Sternocleidomastoid
CGRP	Calcitonin gene-related peptide